Immunophenotype as a prognostic predictor in patients with acute myeloid leukemia
Keywords:
leukemia, myeloid, markers, immunophenotype, prognosis.Abstract
Objective: To determine whether the expression of specific immunophenotypic markers analyzed by flow cytometry influences the prognosis of patients with Acute Myeloid Leukemia (AML) at the Teodoro Maldonado Carbo Specialty Hospital. Materials and methods: An observational, retrospective study with a non-experimental design was carried out in 52 patients diagnosed with AML evaluated by outpatient service at the "Teodoro Maldonado Carbo" Specialty Hospital, during the period from January 2018 to December 2020. The data from the medical records found in the As400 platform of the aforementioned hospital were used. Results: Of a sample, the overall age was 49.5 years, 67% were of gender. The most frequent markers were: CD117 (75%), and CD34 (73.8%) marking the myeloid lineage as the affected one. Most of the markers showed a weak expression, being CD33 (granulocytic marker) the one that most frequently had a strong expression. Among the markers studied, most did not show a significant correlation with the mortality and complications variables, except for the CD105 marker, which showed a strong positive correlation with mortality. Conclusion: The expression of the CD105 marker was the only one that had a significant correlation with a worse course of the disease, the other markers of the panel did not show greater relevance.
Downloads
References
Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet [Internet]. 2018;392(10147):593–606.
Chen W, Luu HS. Immunophenotyping by multiparameter flow cytometry. Methods Mol Biol. 2017;1633:51–73.
Chen X, Cherian S. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis. Clin Lab Med. 2017;37(4):753–69.
Pelcovits A, Niroula R. Acute Myeloid Leukemia: A Review. R I Med J (2013). 2020;103(3):38–40.
Globocan. Ecuador Source: Globocan 2020. Int Agency Reserch Cancer. 2020;563:1–2.
Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. Acute Myeloid Leukemia - Cancer Stat Facts [Internet]. https://seer.cancer.gov/. 2018 [citado el 17 de febrero de 2021].
Barbosa C. Asociación del inmunofenotipo con variables clínicas de impacto pronóstico en una cohorte de pacientes con Leucemias Mieloides Agudas en el Hospital Universitario San Ignacio. (Trabajo de grado presentado para optar al titulo de Bacteriólogo). Colombia, 2020.
Gutiérrez R. La citogenética y el inmunofenotipo como factores pronosticos en la leucemia mieloide aguda (LMA). (Trabajo de grado presentado para optar al titulo de Médico Internista). México, 2020.
Pino D, Macías-Abrahm C, Lahera-Sánchez T, Marsán-Suárez V, Sánchez-Segura M, del-Valle L, Socarras-Ferrer B, Martínez-Machado M. Caracterización inmunofenotípica de pacientes con leucemia mieloide aguda. Revista Cubana de Hematología, Inmunología y Hemoterapia. 2013;30(1): Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/92
Costa Barbosa SF, Costa Ca, Canto Ferreira L, Souza D, Brito TC, Rodri-gues JA et al. Aspectos epidemiológi-cos dos casos de leucemia e linfomas em jovens e adultos atendidos em hos-pital de referência para câncer em Be-lém, Estado do Pará, Amazônia, Brasil. Rev Pan-Amaz Saude 2015; 6(1):43-50.
Kauer J, et al. CD105 (Endoglin) as negative prognostic factor in AML. Sci Rep. 2019; 9: 18337.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 AVFT – Archivos Venezolanos de Farmacología y Terapéutica
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.